Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 14, 2015; 21(18): 5647-5653
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5647
Table 1 Characteristics of the 29 patients included in the analysis
CharacteristicsValue
Age (yr)53.6 (50.6, 60.9)
Male20 (68.9)
HCV infection duration (yr)13.5 (5.6, 17.2)
Geographic origin
North Africa6 (20.7)
Sub-Saharan Africa5 (17.2)
West Indies1 (3.4)
Asia1 (3.4)
Eastern Europe1 (3.4)
Northern Europe15 (51.7)
HCV genotype
18 (27.6)
1a4 (13.8)
1b6 (20.7)
44 (13.8)
4a5 (17.2)
4c2 (6.9)
Liver biopsy (n = 20)
Activity Metavir score
03 (15)
19 (45)
27 (35)
31 (5)
Fibrosis Metavir score
16 (30)
27 (35)
34 (20)
43 (15)
Steatosis12 (60)
Serum biomarkers (n = 18)
Actitest0.51 (0.41, 0.66)
Fibrotest0.64 (0.47, 0.76)
Activity Metavir score
01 (5.6)
13 (16.7)
28 (44.4)
36 (33.3)
Fibrosis Metavir score
03 (16.7)
12 (11.1)
24 (22.2)
33 (16.7)
46 (33.3)
Fibroscan (kPa) (n = 20)7.3 (6.2, 12.4)
> 10 kPa8 (40)
Hypertension7 (24.1)
Dyslipidemia2 (6.9)
Alcohol consumption
No25 (86.2)
Rarely2 (6.9)
Regular2 (6.9)
Vitamin D serum level (visit 1, ng/mL)15 (11, 23)
HCV viremia at inclusion (Log)6.02 (5.80, 6.29)